¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Other specified transitory neonatal endocrine disorders"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
¿µ¹® endocrine gland ÇÑ±Û ³»ºÐºñ»ù
¼³¸í   
  ½ÅüÀÇ ³»ºÎ·Î ºÐºñ°¡ µÇ¾î¼­ ´Ù¸¥ ¼¼Æ÷ÀÇ ±â´ÉÀ̳ª È°¼ºÀÇ º¯È­¸¦ ÀÏÀ¸Å°´Â ¹°ÁúÀΠȣ¸£¸óÀ» ºÐºñÇϴ °÷À» À̸£´Â ¸»ÀÌ´Ù. ´ëÇ¥ÀûÀΠ³»ºÐºñ»ùÀº °©»ó»ù, ºÎ°©»ó»ù, ºÎ½Å, ÀÌÀÚ, ³úÇϼöü, ³­¼Ò, °íȯ, ¼Ö¹æ¿ï»ù, °¡½¿»ù µîÀÌ´Ù.
  
  ¸¶Áö¸·¿¡ ³ª¿À´Â 2°³ÀÇ ±â°üÀº ³»ºÐºñ ±â´ÉÀ» Çϴ °ÍÀ¸·Î »ý°¢ÀÌ µÇÁö¸¸ È®½ÇÈ÷ ±×°ÍÀÌ ¹«½¼ ±â´ÉÀ» Çϴ Áö¿¡ ´ëÇØ¼± ¾ÆÁ÷±îÁö Á¤È®ÇϰԠ¹àÇôÁöÁö ¾Ê°í ÀÖ´Ù.
  
  ³»ºÐºñ»ù
¿µ¹® neonatal intensive care center ÇÑ±Û ½Å»ý¾Æ ÁýÁßÄ¡·á½Ç
¼³¸í   
  ¹Ì¼÷¾Æ³ª °¡»ç »óÅÂÀÇ Ãâ»ê¾Æ¸¦ ÁýÁßÀûÀ¸·Î º¸»ìÇǰí Ä¡·áÇϴ ±â°ü.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • endocrine
    1. ³»ºÐºñ- 2. È£¸£¸ó-
  • endocrine cataract
    ³»ºÐºñ¹é³»Àå
  • endocrine exophthalmos
    ³»ºÐºñ¾È±¸µ¹Ãâ(Áõ)
  • endocrine gland
    ³»ºÐºñ»ù, ³»ºÐºñ¼±
  • endocrine organ
    ³»ºÐºñ±â°ü
  • endocrine system
    ³»ºÐºñ°èÅë, ³»ºÐºñ°è
  • endocrine therapy
    ³»ºÐºñ¿ä¹ý
  • multiple endocrine adenomatosis
    ´Ù¹ß¼º³»ºÐºñ»ùÁ¾Áõ
  • multiple endocrine neoplasia
    ´Ù¹ß³»ºÐºñ»ùÁ¾¾ç
  • multiple endocrine neoplasia 1
    ´Ù¹ß³»ºÐºñ»ùÁ¾¾ç1Çü
  • multiple endocrine neoplasia 2
    ´Ù¹ß³»ºÐºñ»ùÁ¾¾ç2Çü
  • multiple endocrine neoplasia 3
    ´Ù¹ß³»ºÐºñ»ùÁ¾¾ç3Çü
  • early neonatal mortality rate
    Á¶±â½Å»ý¾Æ»ç¸Á·ü
  • neonatal
    ½Å»ý¾Æ-
  • neonatal alloimmune thrombocytopenia
    ½Å»ý¾Æµ¿Á¾¸é¿ªÇ÷¼ÒÆÇ°¨¼Ò(Áõ)
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • endocrine
    ³»ºÐºñ-
  • multiple endocrine neoplasia
    º¹ÇÕ³»ºÐºñ»ù½Å»ý¹°
  • neonatal intensive care center
    ½Å»ý¾ÆÁýÁßÄ¡·á½Ç
  • neonatal death
    ½Å»ý¾Æ»ç¸Á
  • neonatal hepatitis
    ½Å»ý¾Æ°£¿°
  • neonatal infection
    °«³­¾Ö°¨¿°, ½Å»ý¾Æ°¨¿°
  • neonatal mortality
    ½Å»ý¾Æ»ç¸Á·ü
  • neonatal period
    ½Å»ý¾Æ±â
  • neonatal screening
    ½Å»ý¾Æ¼±º°°Ë»ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • transitory fiber
    ÀÌÇ༶À¯
  • transitory hydrocele
    Àϰú¼º¹°À½³¶Á¾
  • transitory paralysis
    Àϰú¼º¸¶ºñ
  • multiple endocrine adenomatosis
    ´Ù¹ß³»ºÐºñ»ùÁ¾Áõ
  • endocrine cataract
    ³»ºÐºñ¹é³»Àå
  • endocrine
    ³»ºÐºñ
  • endocrine exophthalmos
    ³»ºÐºñ´«µ¹Ãâ(Áõ)
  • endocrine gland
    ³»ºÐºñ»ù
  • endocrine organ
    ³»ºÐºñ±â°ü
  • endocrine system
    ³»ºÐºñ°èÅë
  • endocrine therapy
    ³»ºÐºñ¿ä¹ý
  • multiple endocrine neoplasia
    º¹ÇÕ³»ºÐºñ»ù½Å»ý¹°
  • neonatal anemia
    ½Å»ý¾ÆºóÇ÷
  • neonatal asphyxia
    ½Å»ý¾ÆÁú½Ä
  • neonatal atelectasis
    ½Å»ý¾Æ¹«±âÆó
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • gastrointestinal endocrine cell
    À§Ã¢ÀÚ³»ºÐºñ¼¼Æ÷
  • DSM-I=Diagnostic and Statistical Manual of Mental Disorders-I
    Á¤½ÅÀå¾Ö(º´)Áø´ÜÅë°èÆí¶÷ Á¦ 1ÆÇ
  • SADS, Schedule for Affective Disorders and Schizophrenia
    Á¤µ¿Àå¾Ö¿Í Á¤½ÅºÐ¿­º´ÀÇ Áø´ÜÀ» À§ÇÑ ¸ñ·Ï
  • adrenal disorders
    ºÎ½ÅÀå¾Ö, ºÎ½ÅÁúȯ.
  • genetic disorders
    À¯Àü¼º Àå¾Ö(Áúȯ)(ë¶îîàõ î¡äô)
  • hemostatic disorders
    Ç÷¾×ÀÀ°íÁúȯ
  • hypersensitivity disorders
    °ú¹Î¼º Áúȯ(ΦÚÂàõ òðü´)
  • immune disorders
    ¸é¿ªÀå¾Ö(Øóæ¹î¡äô)
  • platelet function disorders
    Ç÷¼ÒÆÇ±â´ÉÀÌ»óÁúȯ
  • postpartum disorders
    »êÈÄ Àå¾Ö(º´)
  • psychogenic voice disorders
    ½ÉÀÎ(¼º) À½¼ºÀå¾Ö
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • specified disease
    ƯÁ¤µÈ Áúº´(÷åïÒ¡­òðÜ»), ƯÀÌÁúȯ(÷åì¶òðü´)
  • atypical, mixed or other personality
    ºñÁ¤Çü ³»Áö È¥ÀçÇü ¶Ç´Â ±âŸ ÀΰÝ
  • shock and other somatic treatment
    Ãæ°Ý ¹× ±âŸ ½Åüġ·á
  • paralysis, transitory
    Àϰú¼º¸¶ºñ
  • transitory carrier
    Àϰú¼º º¸±ÕÀÚ(ÊÙËÓË»Ëö).
  • transitory fever
    Àϰú¼º ¿­(¡­æð)
  • transitory fever of newborn
    ½Å»ý¾Æ(ãæßæä®)Àϰú¼º¿­.
  • transitory fever of newborn
    ½Å»ý¾Æ(ãæßæä®)Àϰú¼º¿­
  • transitory fiber
    ÀÌÇ༶À¯
  • transitory hydrocele
  • transitory paralysis
    Àϰú¼º¸¶ºñ
  • transitory postepileptic paralysis
    °£ÁúÈÄÀϰú¼º¸¶ºñ(ÊÖòðý­ìéΦàõ Ýö).
  • cortical endocrine cell
    °ÑÁú³»ºÐºñ¼¼Æ÷
  • discrete multiple endocrine adenomatosis syndrome
    ºÐ¸®¼º ´Ù¹ß ³»ºÐºñ¼±Á¾ ÁõÈıº(ÝÂìÆàõÒýÛ¡Ò®ÝÂù²àÍðþñøý¦ÏØ).
  • endocrine
    ³»ºÐºñ(Ò®ÝÂÝô)
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Transitory fiber
    ÀÌÇ༶À¯
    [¿¾ ¿ë¾î] ÀÌÇàºÎ¼¶À¯
  • Neonatal period
    ½Å»ý¾Æ±â
    [¿¾ ¿ë¾î] ½Å»ý¾Æ±â
  • Neonatal line
    ù¼ºÀå¼±
    [¿¾ ¿ë¾î] ½Å»ý¼±
  • Cortical endocrine cell
    °ÑÁú³»ºÐºñ¼¼Æ÷
    [¿¾ ¿ë¾î] ÇÇÁú³»ºÐºñ¼¼Æ÷
  • ENDOCRINE GLAND
    ³»ºÐºñ»ù
    [¿¾ ¿ë¾î] ³»ºÐºñ¼±
  • ENDOCRINE GLANDS
    ³»ºÐºñ»ù
    [¿¾ ¿ë¾î] ³»ºÐºñ¼±
  • Medullary endocrine cell
    ¼ÓÁú³»ºÐºñ¼¼Æ÷
    [¿¾ ¿ë¾î] ¼öÁú³»ºÐºñ¼¼Æ÷
  • Endocrine cell of pineal gland
    ¼Û°úü³»ºÐºñ¼¼Æ÷
    [¿¾ ¿ë¾î] ¼Û°úü³»ºÐºñ¼¼Æ÷
  • Gastrointestinal endocrine cell
    À§Ã¢ÀÚ³»ºÐºñ¼¼Æ÷
    [¿¾ ¿ë¾î] À§Ã¢ÀÚ³»ºÐºñ¼¼Æ÷
  • Pancreatic endocrine cell
    ÀÌÀÚ³»ºÐºñ¼¼Æ÷
    [¿¾ ¿ë¾î] ÃéÀå³»ºÐºñ¼¼Æ÷
  • Endocrine cell
    ³»ºÐºñ¼¼Æ÷
    [¿¾ ¿ë¾î] ³»ºÐºñ¼¼Æ÷
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • transitory complex
    õÀ̺¹ÇÕü(ôÃì¹ÜÜùêô÷)
  • endocrine gland
    ³»ºÐºñ¼±(Ò®ÝÂÝôàÍ)
  • endocrine hormones
    ³»ºÐºñ¼±(Ò®ÝÂÝôàÍ) È£¸£¸ó
  • endocrine system
    ³»ºÐºñ¼±(Ò®ÝÂù²àÊ) ½Ã½ºÅÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • transitory
    ÀÌÇàÀÇ
  • endocrine
    ³»ºÐºñÀÇ
  • endocrine disease
    ³»ºÐºñÁúȯ
  • neonatal
    ½Å»ý¾ÆÀÇ, ½Å»ý¾Æ
  • neonatal atelectasis
    ½Å»ý¾Æ¹«±âÆó
  • neonatal jaundice
    ½Å»ý¾ÆÈ²´Þ
  • neonatal mortality
    ½Å»ý¾Æ»ç¸Á(·ü)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
MEN Multiple Endocrine Neoplasia
  ; AD Trait
  1. MEN Type I(= Wermer Syndro...
DOC date of conception; deoxycholate; deoxycorticosterone; died of other causes; disorders of cornificat...
OND Ophthalmic Nursing Diploma; orbitonasal dislocation; other neurological disorders
PRAGMATIC pregnancy, rheumatoid arthritis, acromegaly, glucose metabolism disorders, mechanical injury, amyloi...
ad add [Lat. adde] let there be added [up to a specified amount] [Lat. addetur]; axiodistal; right ear ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
TIA transitory ischaemic attack
EDNOS Eating Disorder Not Otherwise Specified
NOS Not Otherwise Specified
PDD-NOS Pervasive Developmental Disorder Not Otherwise Specified
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
  • P72.8
    Other specified transitory neonatal endocrine disorders
    ±âŸ ¸í½ÃµÈ Àϰú¼º ½Å»ý¾Æ ³»ºÐºñ Àå¾Ö
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • American Academy of Craniomandibualr Disorders
    ¹Ì±¹ µÎ°³ÇϾÇÀå¾ÖÇÐȸ
  • transitory carrier
    Àϰú¼º º¸±ÕÀÚ
  • transitory paralysis
    Àϰú¼º ¸¶ºñ
  • form-other
    Çü½Ä»óÀÇ ¸ñ
  • other abnormality
    ±âŸ ÀÌ»ó
  • other craniofacial disorder
    ´Ù¸¥ µÎ°³ ¾È¸é Àå¾Ö
  • other facial structure
    ´Ù¸¥ ¾È¸é ±¸Á¶¹°
  • other mycoses
    ±âŸ Áø±ÕÁõ
  • discrete multiple endocrine adenomatosis syndrome
    ºÐ¸®¼º ´Ù¹ß ³»ºÐºñ ¼±Á¾ ÁõÈıº
  • endocrine diabetes
    ³»ºÐºñ¼º ´ç´¢º´
  • endocrine disorder
    ³»ºÐºñ Àå¾Ö
  • endocrine exophthalmos
    ³»ºÐºñ¼º ¾È±¸ µ¹Ãâ, ³»ºÐºñ¼º ¾È±¸ µ¹ÃâÁõ
  • endocrine gland
    ³»ºÐºñ »ù, ³»ºÐºñ ¼±
    1. Ç¥¸é°ú ¿¬°áµÊÀÌ ¾øÀÌ Ç÷°ü ¼ÓÀ¸·Î ºÐºñÇÏ´Â »ù. 2. È£¸£¸óÀ» ºÐºñÇÏ´Â ¼±. ¿ÜºÐºñ¼±°ú °°Àº µµ°üÀÌ ¾ø°í È£¸£¸óÀº Á÷Á¢ ü¾× ¼ÓÀ¸·Î ¹èÃâµÈ´Ù.
  • endocrine organ
    ³»ºÐºñ ±â°ü
    ³»ºÐºñ ±â´ÉÀ» ´ã´çÇÏ´Â ½Åü ±â°üÀ¸·Î ³úÇϼöü, ½Ã»ó ÇϺÎ, °©»ó¼±, ÃéÀå, ºÎ½Å, ºÎ°©»ó¼±°ú »ý½Ä ±â°üÀÌ ÀÖ´Ù.
  • endocrine system
    ³»ºÐºñ°è
    ÀÎüÀÇ Á¶Àý ±â´ÉÀ¸·Î ¼¼Æ÷°£ÀÇ ´ëÈ­¸¦ È­ÇÐ ¹°ÁúÀΠȣ¸£¸óÀ» ÅëÇØ¼­ È­ÇÐÀûÀÎ ½ÅÈ£¸¦ ÀÌ¿ëÇÏ¿© Ç¥Àû ¼¼Æ÷µé¿¡ ÀÛ¿ëÇÑ´Ù. ÈçÇÑ ³»ºÐºñ°è ÀÌ»óÀº ºñÁ¤»óÀûÀÎ ¼ºÀå, ¿¡³ÊÁö ¼öÁØ º¯È­ ¿Âµµ º¯È­¿¡ÀÇ ºÎÀûÀÀ ¹× ¼³¸íµÇÁö ¾Ê´Â üÁß º¯È­·Î ³ªÅ¸³­´Ù. ´Ù´¢, °úµµÇÑ °¥Áõ, üÁß °¨¼Ò¸¦ µ¿¹ÝÇÑ ½Ä¿å °ú´Ù´Â ´ç´¢º´ÀÇ Æ¯Â¡ÀÌ´Ù. ½Ã·Â º¯È­, ½ÅÀå ±â´ÉÀå¾Ö, »çÁöÀÇ Ç÷¾× ¼øÈ¯ °¨¼Ò´Â Àå±â°£ÀÇ ´ç´¢·Î ÀÎÇÑ ÁøÇàµÈ Ç÷°ü °æÈ­ÀÇ Áõ»óÀÌ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
transitory Marked by the quality of passing away: evanescent, transient, of brief duration: existing momentarily: temporary.
(18 Nov 1997)
endocrine disorders Disorders which involve the over-production or under-production of hormone substances from an endocrine gland. Some examples include diabetes, hypothyroidism, hyperthyroidism, hyperparathyroidism, Cushing's disease, Cushing's syndrome and acromegaly.
(27 Sep 1997)
other-directed Pertaining to a person readily influenced by the attitudes of others.
(05 Mar 2000)
transferases (other substituted phosphate groups) <enzyme> A class of enzymes that transfers substituted phosphate groups.
Registry number: EC 2.7.8
(12 Dec 1998)
bone diseases, endocrine Diseases of the bones related to hyperfunction or hypofunction of the endocrine glands.
(12 Dec 1998)
multiple endocrine adenomatosis The presence of functioning tumours in more than one endocrine gland, commonly the pancreatic islets and parathyroid glands, which may be associated with Zollinger-Ellison syndrome; dominant inheritance.
Synonym: multiple endocrine adenomatosis.
(05 Mar 2000)
multiple endocrine deficiency syndrome <syndrome> Acquired deficiency of the function of several endocrine glands, usually on an auto-immune basis.
Synonym: multiple glandular deficiency syndrome.
(05 Mar 2000)
multiple endocrine neoplasia (type I) This is a hereditary disorder in which two or more of the following glands: parathyroid, pancreas, pituitary, adrenals or thyroid develop hyperplasia or a tumour.
(type II) This is a hereditary disorder in which two or more of the following glands: thyroid, adrenal or parathyroid, develop overgrowth (hyperplasia) or malignant cells (cancer). The underlying cause is genetic and a positive family history for this illness is a risk factor.
Incidence: approximately 3 in 100,000 people in the general population.
Origin: Gr. Plassein = to form
(27 Sep 1997)
multiple endocrine neoplasia 1 <radiology> Multiple endrocrine neoplasia syndrome three P's.
Pituitary adenoma, 65% can develop Cushing's, acromegaly, prolactinoma, parathyroid hyperplasia / adenoma, 88% can develop hyper-PTH
pancreatic isleT-cell tumour, gastrinoma (Z-E) most common, 50% of Z-E can develop MEN-1, inconstant features: bronchial/intestinal carcinoid, thyroid adenoma, adrenal cortical tumour, lipoma, thymoma tissue expression
Primary hyperparathyroidism (90%), Gastrinoma (30%), Prolactinoma (15%), Other (10%).
Synonym: Wermer syndrome
(12 Dec 1998)
multiple endocrine neoplasia 2 <radiology> Multiple endocrine neoplasia syndrome, medullary thyroid carcinoma, usually multifocal; metastasis to local nodes, lung, liver, usually calcify in liver, pheochromocytoma, almost always bilateral, parathyroid hyperplasia, may be secondary to calcitonin secreted by medullary thyroid carcinoma inconstant feature: adrenal cortical hyperplasia
Synonym: Sipple syndrome
(12 Dec 1998)
multiple endocrine neoplasia 3 <radiology> Multiple endocrine neoplasia syndrome (type 2B, type 3), medullary thyroid carcinoma, pheochromocytoma, marfanoid habitus (Cf: Marfan syndrome), mucosal neuromas, neurofibromas, ganglioneuromatosis coli More info: MEN syndrome 2B
Synonym: Schimke, marfanoid syndrome
(12 Dec 1998)
multiple endocrine neoplasia type 1 A rare syndrome characterised by hyperplasia and/or neoplasms of the pituitary, parathyroid glands, and pancreatic islets. Hyperparathyroidism occurs in 90% of the cases and is usually the first manifestation of the syndrome. The most frequent pancreatic manifestation is gastrinoma typically leading to zollinger-ellison syndrome. The appearance of this condition has been limited to the loss of allelic heterozygosity at the 11q13 locus on the long arm of chromosome 11. Patients overall exhibit long survival times. Chemotherapy is rare and surgical management is generally dependent on the genetic expression in individual patients.
(12 Dec 1998)
multiple endocrine neoplasia type 2 <syndrome> This is a hereditary disorder in which two or more of the following glands: thyroid, adrenal or parathyroid, develop overgrowth (hyperplasia) or malignant cells (cancer). The underlying cause is genetic and a positive family history for this illness is a risk factor.
Incidence: approximately 3 in 100,000 people in the general population.
(27 Sep 1997)
multiple endocrine neoplasia type 2a A type of multiple endocrine neoplasia characterised by a virtually 100% incidence of medullary thyroid carcinoma, a 50% incidence of pheochromocytoma, and a lesser incidence of parathyroid adenomas associated with hyperparathyroidism. The condition is always transmitted through autosomal dominant inheritance. Genetic testing can identify individuals with the trait in early infancy. Treatment is usually excision of the enlarged parathyroid glands.
(12 Dec 1998)
multiple endocrine neoplasia type 2b A type of multiple endocrine neoplasia occurring as an isolated congenital presentation or as a distinct autosomal dominant disease. It is characterised by the 100% incidence of medullary thyroid carcinoma and frequent pheochromocytomas; patients seldom exhibit hyperparathyroidism. It is distinguished from men 2a by its characteristic physical appearance resulting from numerous neural defects including mucosal neuromas of the eyelids, lips, and tongue. The neural abnormalities also include widespread neurogangliomatosis of the gastrointestinal tract leading to abnormal gut motility. Treatment usually requires total thyroidectomy following evaluation for the presence of pheochromocytomas.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • neonatal
    ½Å»ý¾ÆÀÇ
  • transitory
    ¼ø½Ä°£ÀÇ; ¹«»óÇÑ
  • endocrine
    ³»ºÐºñÀÇ;³»ºÐºñ¹°;È£¸£¸ó;³»ºÐºñ¼±
  • endocrine gland
    (»ý¸®)³»ºÐºñ¼±
  • transitory
    ÀϽÃÀÇ;ÀϽÃÀûÀÎ;¿À·¡°¡Áö ¾Ê´Â;µ¡¾ø´Â;¹«»óÇÑ
  • each other
    ¼­·Î
  • in some way or other
    ¾î¶»°Ô ÇØ¼­µçÁö
  • other
    ±×¹ÛÀÇ
  • some other time
    ¾ðÁ¨°¡ µý³¯¿¡(=some other day)
  • t'other
    ¶Ç Çϳª
  • A.N. Other
    ÀÍ¸í¾¾;¼±¼ö ¹ÌÁ¤
  • other
    µý;´Ù¸¥;´ÙÀ½ÀÇ;³ª¸ÓÁöÀÇ;every ~ Çϳª°É·¯;none ~ than ´Ù¸§ ¾Æ´Ñ;the ~ day(night)ÀÏÀü(¿äÀü³¯ ¹ã)¿¡;the ~ party »ó´ë¹æ;the ~ side (¹Ì±¹¿¡¼­ º») À¯·´;the ~ world ³»¼¼;Àú½Â
  • other
    ±×·¸Áö ¾Ê°í;µý ¹æ¹ýÀ¸·Î
  • other
    µý °Í(»ç¶÷);´Ù¸¥ Çϳª;³ª¸ÓÁö °Í;of all ~s ¸ðµç °Í(»ç¶÷)Áß¿¡¼­ ƯÈ÷;some ... or ~ ¹«¾ð(´©±º,¾îµò)°¡
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á